Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels. - Wikidata - awgldk - TriplyDB

Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels.

Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels.

http://www.wikidata.org/entity/Q37075113

about

Human infection with Strongyloides stercoralis and other related Strongyloides species.Importance of a Rapid and Accurate Diagnosis in Strongyloides Stercoralis and Human T-Lymphotropic Virus 1 Co-infection: A Case Report and Review of the Literature.

P2860

Q40674060-D066D503-33D8-4150-831C-C027F0C95CBC Q47098391-F16C6A61-D3BB-4072-AD95-7BAE33A18F0C

P2860

Treatment of strongyloidiasis in HTLV-1 and Strongyloides stercoralis coinfected patients is associated with increased TNFα and decreased soluble IL2 receptor levels.

http://www.wikidata.org/entity/Q37075113

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@en

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@nl

type

label

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@en

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@nl

prefLabel

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@en

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@nl

P1433

Q37075113-4E72C510-3877-48EF-B74C-3C7D81C721FB

P1476

Q37075113-4F3CE4C7-6C5A-4C10-90AA-CA753EBEDF40

P2093

Q37075113-08201A69-33CF-4EB3-B160-D1682131CEE7

Q37075113-0AD1A7E8-2563-4B01-B69D-5768C276F6BE

Q37075113-1A1B83BA-8EA6-44F2-9186-399988BF767F

Q37075113-4487B569-885F-4B05-9155-464AB3D14436

Q37075113-6F3AE1B8-875E-46CC-9B86-1C5C7EE51102

Q37075113-739019F7-9C55-4CE4-9A23-4745BE46653E

Q37075113-A85E4B23-6F3E-45FE-B470-D5D0B15C95DC

Q37075113-B2E37F5A-F2AC-4941-9002-84E80761F5C9

Q37075113-CB4333DA-EBCD-4FD5-BEB2-E87F5876E9CF

P2860

Q37075113-08921244-F716-4E2E-A6A9-253FBECF4658

Q37075113-13CF962D-3011-432F-B53E-BE56C0E7C316

Q37075113-1E30A41F-9401-43E1-A168-504D375BE49F

Q37075113-20E0D544-7B44-4498-9BA7-7F93DDF361E9

Q37075113-4E40DF34-3355-4526-911F-124BBE5E4007

Q37075113-59AEF687-4937-4F58-8B67-22532E7A3346

Q37075113-7A84CE37-1A1D-4977-9781-C76D289AB8C8

Q37075113-8A5A7CA9-B628-4CF3-8E88-AD474E604777

Q37075113-93307411-CAF4-45ED-8A36-D183B93C1D3E

Q37075113-9D9FB508-CB10-4D9D-8C5E-D630566A94BD

P304

Q37075113-A5E01A1C-777C-498E-B81F-D48BB1101E4C

P31

Q37075113-931A2560-A847-466B-9EC1-188E1FCCF169

P356

Q37075113-14BF54D5-A9C1-4D21-9AF8-5B5FE50DABF7

P433

Q37075113-01EBF839-50E9-48E3-B4D7-316546122201

P478

Q37075113-202C09DB-72F8-4E7F-8E3A-CE46F6878F21

P577

Q37075113-0B6516D8-46AF-43B5-BAD2-66489FDE0D4D

P698

Q37075113-491E2404-3990-4098-81B5-F7171E0C5C4F

P921

Q37075113-0C20789A-121C-450B-81C1-AAAF78FC5D35

Q37075113-57BC24E9-518A-4B15-B024-4424DAFFCC13

Q37075113-D9AEFD8B-5B97-4FA2-9AB4-C11D73A9B602

P932

Q37075113-B8432E0E-A670-4D98-8208-D42F5F2F9EC8

P356

P1433

Transactions of the Royal Society of Tropical Medicine and Hygiene

P1476

Treatment of strongyloidiasis ...... d soluble IL2 receptor levels.

@en

P2093

Andrea Bacellar

http://www.w3.org/2001/XMLSchema#string

Aurélia Porto

http://www.w3.org/2001/XMLSchema#string

Edgar Carvalho

http://www.w3.org/2001/XMLSchema#string

Fernanda Salles

http://www.w3.org/2001/XMLSchema#string

Glória Orge

http://www.w3.org/2001/XMLSchema#string

Michael Sundberg

http://www.w3.org/2001/XMLSchema#string

Mirla Amorim

http://www.w3.org/2001/XMLSchema#string

Márcia Lima

http://www.w3.org/2001/XMLSchema#string

Silvane Santos

http://www.w3.org/2001/XMLSchema#string

P2860

Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers

Prevalence of erectile dysfunction in HTLV-1-infected patients and its association with overactive bladder

Clinical manifestations associated with HTLV type I infection: a cross-sectional study

Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.

Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru.

Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP.

Helminthic infection down-regulates type 1 immune responses in human T cell lymphotropic virus type 1 (HTLV-1) carriers and is more prevalent in HTLV-1 carriers than in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection.

Prevalence of the overactive bladder syndrome by applying the International Continence Society definition.

Involvement of IL-2/IL-2R system activation by parasite antigen in polyclonal expansion of CD4(+)25(+) HTLV-1-infected T-cells in human carriers of both HTLV-1 and S. stercoralis.

P304

526-529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/TRSTMH/TRT052

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23843560

http://www.w3.org/2001/XMLSchema#string

P921

Human T-lymphotropic virus 1

strongyloidiasis

Strongyloides stercoralis

P932

3735360

http://www.w3.org/2001/XMLSchema#string